Helen of Troy (HELE) is a Top-Ranked Momentum Stock: Should You Buy?

Helen of Troy (HELE) is rated #3 (Hold) by Zacks, with A grades for both its Momentum and VGM Style Scores. Shares gained 17.9% over four weeks, two analysts raised fiscal 2027 earnings estimates in the past 60 days, and the consensus estimate rose $0.15 to $3.69 per share; the company’s average earnings surprise is reported at +207.7%. The article presents the stock as one to watch, rather than reporting a new company event or a buy recommendation from Zacks.

Analysis

The signal is estimate revision drift, not the A momentum score: a small number of upward FY27 revisions may attract short-horizon quant flows, but the stock’s sharp recent advance raises the bar for incremental good news. The #3 (Hold) rating also tempers the promotional framing. The reported +207.7% average earnings surprise is backward-looking and may be skewed by the size or comparability of prior estimates; it is not evidence of durable earnings power. The cited long-run Zacks performance statistic is not a stock-specific return forecast.

Over days to weeks, momentum can persist, but crowded positioning and a pause in estimate upgrades could make the move vulnerable to reversal. Over the next 1–3 months, verify whether revisions broaden and whether upcoming results support them with sales, gross-margin and guidance progress—not just EPS beats. No structural advantage or competitor displacement is established here; any read-through to consumer-products peers such as Newell Brands (NWL) or SharkNinja (SN) is limited without category-level data. Over 6–18 months, the key question is whether earnings growth is repeatable across HELE’s portfolio, which this article does not establish.

Key Decisions for Investors

• Do not chase HELE solely on the momentum score or recent price strength. For an existing position, maintain exposure only if the thesis is supported by operating results; consider trimming into further sharp strength rather than treating the article as a new fundamental catalyst.
• Set an alert for the next earnings release and estimate revisions: constructive confirmation requires sustained FY27 EPS upgrades alongside sales and margin evidence. A reversal in revisions, weaker guidance, or deterioration in those operating metrics would falsify the momentum thesis.
• No pair or options trade is warranted from this evidence alone. Reassess after verifying the composition of the earnings surprises, the breadth of analyst revisions, and current valuation; those missing inputs determine whether the move is under- or overextended.